237 related articles for article (PubMed ID: 30256787)
1. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
[TBL] [Abstract][Full Text] [Related]
2. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
3. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
[TBL] [Abstract][Full Text] [Related]
5. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options.
Brown RE; Buryanek J; Tammisetti VS; McGuire MF; Csencsits-Smith K
Oncotarget; 2016 Jul; 7(27):41612-41621. PubMed ID: 27223432
[TBL] [Abstract][Full Text] [Related]
6. PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.
Liu XL; Zhang GM; Huang SS; Shi WH; Ye LX; Ren ZL; Zhang JJ; Liu SW; Yu L; Li YL
Acta Pharmacol Sin; 2022 Sep; 43(9):2397-2409. PubMed ID: 35165399
[TBL] [Abstract][Full Text] [Related]
7. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
8. Unconventional mechanism of action and resistance to rapalogs in renal cancer.
Yang J; Butti R; Cohn S; Toffessi-Tcheuyap V; Mal A; Nguyen M; Stevens C; Christie A; Mishra A; Ma Y; Kim J; Abraham R; Kapur P; Hammer RE; Brugarolas J
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2310793121. PubMed ID: 38861592
[TBL] [Abstract][Full Text] [Related]
9. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
[TBL] [Abstract][Full Text] [Related]
10. Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.
Sakamoto H; Yamasaki T; Sumiyoshi T; Takeda M; Shibasaki N; Utsunomiya N; Arakaki R; Akamatsu S; Kobayashi T; Inoue T; Kamba T; Nakamura E; Ogawa O
Cancer Med; 2021 Jan; 10(1):119-134. PubMed ID: 33107222
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
13. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia.
Potter SL; Venkatramani R; Wenderfer S; Graham BH; Vasudevan SA; Sher A; Wu H; Wheeler DA; Yang Y; Eng CM; Gibbs RA; Roy A; Plon SE; Parsons DW
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27748010
[TBL] [Abstract][Full Text] [Related]
16. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
17. Differentiating mTOR inhibitors in renal cell carcinoma.
Pal SK; Quinn DI
Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
[TBL] [Abstract][Full Text] [Related]
18. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
[TBL] [Abstract][Full Text] [Related]
19. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
20. PTEN Expression, Not Mutation Status in
Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ
Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
